Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS)
Sign Up to like & getrecommendations! Published in 2024 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2024.2361300
Abstract: ABSTRACT Background Package inserts for the FDA-approved dual orexin receptor antagonists (DORAs) suvorexant, lemborexant and daridorexant state that suicide risk should be monitored. It remains unknown whether suicidality is attributed to DORAs. We aim to… read more here.
Keywords: antagonists doras; suicidality; orexin receptor; receptor antagonists ... See more keywords